Innovative
Cancer Treatment
Revolutionary Cancer Treatment
An immunotherapy tailored to each individual
patient that targets their unique neoantigens (new antigens)
–a truly personalized approach to cancer care.
Our goal is to deliver a revolutionary cancer treatment
that places minimal burden on the body.
New Cancer Treatment
In recent years, dramatically advancing genetic analysis technologies have beenbringing about a transformation in cancer immunotherapy. Immunotherapies that use neoantigens̶
developed through worldwide research efforts made possible by progress in genomicanalysis̶
can be considered a long-awaited treatment option for cancer patients and their families.
We aim to provide safer treatments with fewer side effects that overcome the limitations of conventional immunotherapies.
Vision
We aim to develop novel patient-focused therapies centered on cell-based treatments, with an eye toward future applications in regenerative medicine and related fields.
Company
Our core business is the research of diseases and the development of therapies using genes and gene products, cells, and tissues, as well as the commercialization of the resulting outcomes.
News
Latest News
-
Many Neoantigen Candidates Identified by Isolating Circulating Tumor Cells (CTCs) from Blood and Performing Genomic Analysis—Paper Published
-
Notice to Participants Who Took Part in the Feasibility Study of Neoantigen DC Therapy
-
Circulating Tumor Cell–Derived Neoantigen Peptide Study Group Website Now Live
-
Notice of Becoming a Wholly Owned Subsidiary
-
Domestic patent granted
Feel free to contact us
If you have any questions or inquiries about our company, our technologies, or our patents, please don’t hesitate to get in touch with us.